SUVEN PHARMACEUTICALS share price has zoomed 7% and is presently trading at Rs 1,142.3.
Meanwhile, the BSE HEALTHCARE index is at 43,283.1 (up 0.2%).
Among the top gainers in the BSE HEALTHCARE index today are Pfizer (up 4.4%) and FORTIS HEALTHCARE (up 2.0%).
Dr. Reddys (down 1.1%) and Cadila Healthcare (down 1.1%) are among the top losers today.
Over the last one year, SUVEN PHARMACEUTICALS has moved up from Rs 507.6 to Rs 1,142.3, registering a gain of Rs 634.7 (up 125.0%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,815.8 to 43,283.1, registering a gain of 55.6% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 135.7%), Glenmark Pharma (up 127.6%) and SUVEN PHARMACEUTICALS (up 125.0%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 82,554.4 (up 0.2%).
The top gainers among the BSE Sensex today are ITC (up 2.1%) and Bajaj Finserv (up 1.9%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.
In the meantime, NSE Nifty is at 25,299.4 (up 0.3%). Bajaj Finserv and Bajaj Finance are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,075.8 to 82,554.4, registering a gain of 17,478.6 points (up 26.9%).
SUVEN PHARMACEUTICALS net profit fell 49.6% YoY to Rs 608 million for the quarter ended June 2024, compared to a profit of Rs 1,206 million a year ago. Net sales declined 33.6% to Rs 2,307 million during the period as against Rs 3,476 million in April-June 2023.
For the year ended March 2024, SUVEN PHARMACEUTICALS reported 27.0% decrease in net profit to Rs 3,003 million compared to net profit of Rs 4,113 million during FY23. Revenue of the company fell 21.6% to Rs 10,514 million during FY24.
The current Price to earnings ratio of SUVEN PHARMACEUTICALS, based on rolling 12 month earnings, stands at 120.9.
Equitymaster requests your view! Post a comment on "SUVEN PHARMACEUTICALS Gains 7%; BSE HEALTHCARE Index Up 0.2%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!